Accelerate Diagnostics Inc (AXDX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Accelerate Diagnostics Inc stock (AXDX) is currently trading at $0.03. Accelerate Diagnostics Inc PS ratio (Price-to-Sales) is 0.07. Analyst consensus price target for AXDX is $1.50. WallStSmart rates AXDX as Sell.
- AXDX PE ratio analysis and historical PE chart
- AXDX PS ratio (Price-to-Sales) history and trend
- AXDX intrinsic value — DCF, Graham Number, EPV models
- AXDX stock price prediction 2025 2026 2027 2028 2029 2030
- AXDX fair value vs current price
- AXDX insider transactions and insider buying
- Is AXDX undervalued or overvalued?
- Accelerate Diagnostics Inc financial analysis — revenue, earnings, cash flow
- AXDX Piotroski F-Score and Altman Z-Score
- AXDX analyst price target and Smart Rating
Accelerate Diagnostics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Accelerate Diagnostics Inc (AXDX) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales. Concerns around market cap and peg ratio. Significant fundamental concerns warrant caution or avoidance.
Accelerate Diagnostics Inc (AXDX) Key Strengths (1)
Paying less than $1 for every $1 of annual revenue
Supporting Valuation Data
Accelerate Diagnostics Inc (AXDX) Areas to Watch (5)
PEG ratio is negative or unavailable
Losing money on operations
Revenue declining -7.00%, a shrinking business
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Accelerate Diagnostics Inc (AXDX) Detailed Analysis Report
Overall Assessment
This company scores 18/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales. Valuation metrics including Price/Sales (0.07) suggest the stock is attractively priced.
The Bear Case
The primary concerns are PEG Ratio, Operating Margin, Revenue Growth. Some valuation metrics including PEG Ratio (N/A) suggest expensive pricing. Growth concerns include Revenue Growth at -7.00%, which may limit upside. Profitability pressure is visible in Operating Margin at -281.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -281.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -7.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AXDX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AXDX's Price-to-Sales ratio of 0.07x sits near its historical average of 0.07x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is -5% below its historical high of 0.07x set in Feb 2026, and 5% above its historical low of 0.07x in Feb 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Accelerate Diagnostics Inc (AXDX) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Accelerate Diagnostics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 12M with 7% decline year-over-year.
Key Findings
Spending 32% of revenue (4M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 7% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -5M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Accelerate Diagnostics Inc.
Bottom Line
Accelerate Diagnostics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:00:39 AM
About Accelerate Diagnostics Inc(AXDX)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Accelerate Diagnostics, Inc., an in vitro diagnostic company, offers solutions for diagnosing serious infections in the United States, Europe, and the Middle East. The company is headquartered in Tucson, Arizona.